Evaluation of safety and efficacy of 3tc (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase i/ii study

Journal of Infectious Diseases

Volumn 171, Issue 5, 1995, Pages 1166-1171

  Van Leeuwen, Remko ^a,b,c   Katlama, Christine ^a,b,c   Kitchen, Valerie ^a,b,c   Boucher, Charles A B ^a,b,c   Tubiana, Roland ^a,b,c   Mc Bride, Michael ^a,b,c   Ingrand, Didier ^a,b,c   Weber, Jonathan ^a,b,c   Hill, Andrew ^a,b,c   Mc Dade, Hugh ^a,b,c   Danner, Sven A ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; BILIRUBIN; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; LIVER ENZYME; NEOPTERIN; ZALCITABINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BIOPTERIN; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMAN; LAMIVUDINE; MALE; MIDDLE AGE; NEOPTERIN; SUPPORT, NON-U.S. GOV'T; ZALCITABINE;

EID: 0028948198     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.5.1166     Document Type: Article

References (17)

1. Genu-Dellac C, Gosselin G, Aubertin A, et al. 3'-substituted thymine alpha-L-nucleoside derivates as potential antiviral agents: synthesis and biological evaluation. Antiviral Chem Chemother 1991;2:83-92
2. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-5
3. Chang CN, Doong SL, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of(+/-)-2\3'-dideoxy-3'-thiacyti-dine in the inhibition of hepatitis B virus replication. J Biol Chem 1992;267:13938-42
4. Shewach DS, Liotta DC, Schinazi RF. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycyti-dine kinase. Biochem Pharmacol 1993;45:1540-3
5. Tisdale M, Kemp S, Parry N, Larder B. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6
6. van Leeuwen R, Lange JM, Hussey EK, etal. The safety and pharmaco kinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-5
7. Harker A. Evans G, Morris D, Hawley A. A high performance liquid chromatographic assay for 3TC in human serum [abstract PuB 7231]. In: Program and abstracts of the VIII International Conference on AIDS/Third STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992
8. Dawson J, Lagakos S. Analyzing laboratory marker changes in AIDS clinical trials. J Acquir Immune Defic Syndr 1991;4:667-76
9. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3'-azido-3-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575-80
10. Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2’3’-dideoxyadenosine and 2'3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990;47:647-54
11. Klecker RW Jr, Collins JM, Yarchoan RC, et al. Pharmacokinetics of 2', 3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988;28:837-42
12. Nordic Medical Research Council’s HIV Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992;304:13-7
13. Lambert JS, Seidlin M, Reichman RC, et al. 2', 3'-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333-40
14. Bass HZ, Hardy DH, Mitsuyasu RT, et al. The effect of zidovudine treatment on serum neopterin and β2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Acquir Immune Defic Syndr 1992;5:215-21
15. Mulder JW, Krijnen P, Coutinho RA, et al. Serum β2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. Genitourin Med 1991;67:188-93
16. Gao Q, Gu Z, Parniak M, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2'3-dide-oxyinosine and 2'3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2'3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-2
17. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. J Infect Dis 1995;171 (in press)